# Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

> **NCT02040857** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 162 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT02040857
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-05
- **Final completion:** 2024-12-27
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040857, "Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02040857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*